Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 27,848 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo and sham treatment Clear all

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Obesity and Hypogonadism
Interventions: Testosterone, Lifestyle Therapy, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 85 Years · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Type 2
Interventions: Exenatide once weekly suspension, Sitagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more

Conditions: Healthy Volunteers
Interventions: Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Early Menopause, Menopause
Interventions: Nitrate supplementation, placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Postmenopausal Women
Interventions: nitrate rich beetroot juice, nitrate depleted beetroot juice; Drug
Lead sponsor: Penn State University; Other
Eligibility: Up to 70 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Urinary Tract Infections
Interventions: MPC-SHRC, Placebo Oral Tablet; Drug
Lead sponsor: Mission Pharmacal; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Jeffersonville, Indiana • Kalamazoo, Michigan • Lawrenceville, New Jersey + 1 more

Conditions: Bipolar I Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more

Conditions: Liver Fibrosis Due to NASH
Interventions: Placebo, SIM; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 41
States / cities: Phoenix, Arizona • Coronado, California • San Diego, California + 34 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration; Biological · Other
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: QAV680, QAV680 Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Alzheimer´s Disease
Interventions: Lanabecestat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 2,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 77
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more

Conditions: Healthy Subjects
Interventions: Ultrasound stimulation intensity, Ultrasound stimulation site; Device
Lead sponsor: University of Virginia; Other
Eligibility: 25 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Conditions: Healthy
Interventions: Placebo supplement, Citicoline supplement; Dietary Supplement
Lead sponsor: Kyowa Hakko Bio Co., Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cyclosporine ophthalmic emulsion, placebo; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more

Conditions: Alcoholism, Alcohol Dependence, Post-Traumatic Stress Disorder
Interventions: Cognitive-Behavioral Therapy, Naltrexone, Placebo; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions: Upadacitinib 30mg Dose, Upadacitinib Matching Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Psoriasis
Interventions: BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Burbank, California • Miami, Florida • Port Orange, Florida + 4 more

Conditions: COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions: Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas; Drug
Lead sponsor: Roger Alvarez; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Transplant Failure, Heart Transplant Infection
Interventions: Levothyroxine, Normal saline; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Chronic Inducible Urticaria
Interventions: barzolvolimab, Matching Placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 13 more

Search by objective public record fields.

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Lifestyle Intervention and Testosterone Replacement in Obese Seniors

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Influence of Early Menopause on Sympathetic Activation and Cardiovascular Function in Older Women

Postmenopausal Women and Their Endothelium

Phase II Proof of Concept Study in Uncomplicated UTI

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Optimizing Ultrasound-induced Anti-inflammation in Human Subjects

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

iNOPulse for COVID-19

Levothyroxine Supplementation for Heart Transplant Recipients

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria